Advertisement

Molecular and Cellular Biochemistry

, Volume 428, Issue 1–2, pp 139–147 | Cite as

Clinical significance of cathepsin L and cathepsin B in dilated cardiomyopathy

  • Siddharth Mehra
  • Manish Kumar
  • Mansi Manchanda
  • Ratnakar Singh
  • Bhaskar Thakur
  • Neha Rani
  • Sudheer Arava
  • Rajiv Narang
  • Dharamvir Singh Arya
  • Shyam S. Chauhan
Article

Abstract

Dysregulated expression of lysosomal cysteine cathepsins is associated with adverse cardiac remodeling, a characteristic of several cardiovascular diseases. However, the information regarding the role of cysteine cathepsin L (CTSL) and cathepsin B (CTSB) in dilated cardiomyopathy (DCM) is limited. The present study was aimed to investigate the expression of CTSL and CTSB in animal model of doxorubicin (doxo)-induced cardiomyopathy as well as in peripheral blood samples of DCM patients. Cardiac tissue sections from doxo-treated and control rats were used to study the expression of CTSL and CTSB by enzyme assay and immunohistochemistry (IHC). Peripheral blood mononuclear cells (PBMCs) isolated from DCM patients (n = 29) along with age-matched healthy controls (n = 28) were used to assay enzymatic activity of these cathepsins. Activities of these proteases were further correlated with echocardiographic parameters of DCM patients. A significant increase in CTSL activity and protein expression was observed with no changes in CTSB levels in doxo-treated rats as compared to controls. We also observed a drastic increase in the functional activity of cathepsin L+cathepsin B (CTSL+B), CTSL, and CTSB in DCM patients compared to controls (p ≤ 0.001). Increased levels of these proteases exhibited a statistically significant correlation with reduced left ventricular ejection fraction (LVEF) in DCM patients (ρ = −0.58, p = 0.01). For the first time, this study demonstrates a correlation between increased expression of CTSL and CTSB in PBMCs with severity of left ventricular dysfunction in DCM patients. Thus, these proteases may serve as blood-based biomarker of DCM and prove useful in its management.

Keywords

Cathepsin L Cathepsin B Dilated cardiomyopathy PBMCs Doxorubicin Extracellular matrix and cardiac remodeling 

Notes

Acknowledgements

Department of Biotechnology (DBT), Govt. of India (BT/PR7146/MED/30/900/12), New Delhi, India, financially supported this study. Siddharth Mehra is a recipient of Senior Research Fellowship from University Grants Commission (U.G.C), New Delhi, India. The authors like to acknowledge Dr. Anurag Kumar and Dr. Prajwal for their help in formatting the final version of manuscript.

Compliance with ethical standards

Conflict of interest

The authors declared that they have no potential conflicts of interest.

Research involving human participants

All procedures performed in studies involving human participants were in accordance with the ethical standards of the 1964 Helsinki declaration and was approved by medical ethics review board of All India Institute of Medical Sciences, New Delhi, India.

Informed consent

Written informed consent was obtained from all the participants before enrollment. Similarly for the use of animal model in the present study all applicable international, national, and institutional guidelines for the proper care and use of animals were followed.

References

  1. 1.
    Jefferies JL, Towbin JA (2010) Dilated cardiomyopathy. Lancet 375(9716):752–762CrossRefPubMedGoogle Scholar
  2. 2.
    Towbin JA, Bowles NE (2002) The failing heart. Nature 415(6868):227–233CrossRefPubMedGoogle Scholar
  3. 3.
    Taylor MR, Carniel E, Mestroni L (2006). Cardiomyopathy, familial dilated. Orphanet J Rare Dis 1(1):1CrossRefGoogle Scholar
  4. 4.
    Mestroni L, Maisch B, McKenna WJ et al (1999) Guidelines for the study of familial dilated cardiomyopathies. Eur Heart J 20(2):93–102CrossRefPubMedGoogle Scholar
  5. 5.
    Afonso L, Mohammad T, Thatai D (2007) Crack whips the heart: a review of the cardiovascular toxicity of Cocaine. Am J Cardiol 100(6):1040–1043CrossRefPubMedGoogle Scholar
  6. 6.
    Klatsky AL (2009) Alcohol and cardiovascular diseases. Expert Rev Cardiovasc Ther 7(5):499–506CrossRefPubMedGoogle Scholar
  7. 7.
    Jordan MA (2002) Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2(1):1–7CrossRefPubMedGoogle Scholar
  8. 8.
    Takemura G, Fujiwara H (2007) Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49(5):330–352CrossRefPubMedGoogle Scholar
  9. 9.
    Chatterjee K, Zhang J, Honbo N et al (2010) Doxorubicin cardiomyopathy. Cardiology 115(2):155–162CrossRefPubMedGoogle Scholar
  10. 10.
    Carvalho FS, Burgeiro A, Garcia R et al (2014) Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev 34(1):106–135CrossRefPubMedGoogle Scholar
  11. 11.
    Lefrak EA, Pitha J, Rosenheim S et al (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32(2):302–314CrossRefPubMedGoogle Scholar
  12. 12.
    Cheng XW, Shi GP, Kuzuya M et al (2012) Role for cysteine protease cathepsins in heart disease focus on biology and mechanisms with clinical implication. Circulation 125(12):1551–1562CrossRefPubMedGoogle Scholar
  13. 13.
    Muller AL, Dhalla NS (2012) Role of various proteases in cardiac remodeling and progression of heart failure. Heart Fail Rev 17(3):395–409CrossRefPubMedGoogle Scholar
  14. 14.
    Turk B, Turk D, Turk V (2000) Lysosomal cysteine proteases: more than scavengers. BBA Protein Struct Mol Enzymol 1477(1–2):98–111CrossRefGoogle Scholar
  15. 15.
    Turk B, Turk V, Turk D (1996) Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol Chem 378(3–4):141–150Google Scholar
  16. 16.
    Turk B, Turk D, Salvesen GS (2002) Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr Pharm Des 8(18):1623–1637CrossRefPubMedGoogle Scholar
  17. 17.
    Stypmann J, Glaser K, Roth W et al (2002) Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc Natl Acad Sci USA 99(9):6234–6239CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ge J, Zhao G, Chen R et al (2006) Enhanced myocardial cathepsin B expression in patients with dilated cardiomyopathy. Eur J Heart Fail 8(3):284–289CrossRefPubMedGoogle Scholar
  19. 19.
    Zhao G, Li Y, Cui L et al (2015) Increased circulating cathepsin K in patients with chronic heart failure. PLoS ONE 10(8):e0136093CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Liu Y, Li X, Peng D et al (2009) Usefulness of serum cathepsin L as an independent biomarker in patients with coronary heart disease. Am J Cardiol 103(4):476–481CrossRefPubMedGoogle Scholar
  21. 21.
    Krishnamurthy B, Rani N, Bharti S et al (2015) Febuxostat ameliorates doxorubicin-induced cardiotoxicity in rats. Chem Biol Interact 237:96–103CrossRefPubMedGoogle Scholar
  22. 22.
    Schwartzkopff B, Fassbach M, Pelzer B et al (2002) Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 4(4):439–444CrossRefPubMedGoogle Scholar
  23. 23.
    Yu XH, Zhang XG, Li SJ, et al (2005) [The expression and significance of myocardial cathepsin L in dilated cardiomyopathy]. Zhonghua nei ke za zhi 44(7):495–498PubMedGoogle Scholar
  24. 24.
    Arola OJ, Saraste A, Pulkki K et al (2000) Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 60(7):1789–1792PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Siddharth Mehra
    • 1
  • Manish Kumar
    • 1
  • Mansi Manchanda
    • 1
  • Ratnakar Singh
    • 1
  • Bhaskar Thakur
    • 2
  • Neha Rani
    • 3
  • Sudheer Arava
    • 4
  • Rajiv Narang
    • 5
  • Dharamvir Singh Arya
    • 3
  • Shyam S. Chauhan
    • 1
  1. 1.Department of BiochemistryAll India Institute of Medical SciencesNew DelhiIndia
  2. 2.Department of BiostasticsAll India Institute of Medical SciencesNew DelhiIndia
  3. 3.Department of PharmacologyAll India Institute of Medical SciencesNew DelhiIndia
  4. 4.Department of PathologyAll India Institute of Medical SciencesNew DelhiIndia
  5. 5.Department of CardiologyAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations